TECX logo

Tectonic Therapeutic Inc

TECX

Build a strategy around TECX

Accountable AI Logo

Tectonic Therapeutic Inc AI Insights

Informational only. Not investment advice.
As of 2026-01-26

Snapshot

  • Cash of 268M covers 4.3 years of burn at current -62.6M FCF TTM rate - extended runway vs typical biotech[Cash and Equivalents]
  • EV of 94M vs 268M cash = market pricing pipeline at NEGATIVE 175M implied value[Enterprise Value]
  • R&D of 56.3M TTM is 74% of opex - concentrated bet on pipeline with minimal G&A overhead[Research and Development TTM]

Watch Triggers

  • Cash and Equivalents: Falls below 150M or burn rate exceeds 80M annuallyTriggers dilution risk window - runway drops below 2 years
  • Research and Development TTM: Sudden increase >30% or decrease >20%Signals pipeline expansion/acceleration or program termination
  • Issuance of Capital Stock: Any equity raise while trading below cashDestroys value at current prices - signals management desperation

Bull Case

Trading below cash value (EV 94M vs 268M cash) means pipeline is free - any clinical success reprices equity dramatically upward

Enterprise ValueCash and Equivalents

4.3-year runway at current burn eliminates forced dilution risk that destroys most biotech equity holders

Free Cash Flow TTMCash and EquivalentsTotal Debt

Bear Case

Zero revenue with -67.3M net loss TTM - entirely dependent on clinical trial outcomes with high failure rates

Total Revenue TTMNet Income TTM

Market's negative pipeline valuation may reflect informed skepticism about clinical probability of success

Enterprise ValueMarket Cap TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
45%

Leverage TECX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Binary catalyst risk: pipeline success/failure will drive 2-5x move in either direction

1-3ymed
  • Zero revenue pre-commercial biotech
  • 4+ year cash runway removes near-term dilution
  • Negative EV implies free option on pipeline
FCF TTM -62.6M vs 268M cashEV 94M below cash positionP/B 1.35x near liquidation value

Valuation Context

Caveats

Public Strategies Rankings

See how Tectonic Therapeutic Inc ranks across different investment strategies.

Leverage TECX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.